Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.

Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.
复制标题

DOI:
10.1038/s43018-020-00126-z
复制
发表时间:
2020-12
期刊:
影响因子:
22.7
通讯作者:
Jordan CT
Jordan CT
中科院分区:
医学1区
文献类型:
--
作者:
Stevens BM;Jones CL;Pollyea DA;Culp-Hill R;D'Alessandro A;Winters A;Krug A;Abbott D;Goosman M;Pei S;Ye H;Gillen AE;Becker MW;Savona MR;Smith C;Jordan CT

文献摘要

参考文献

被引文献

相似文献

维奈托克联合阿扎胞苷(ven/aza)已成为治疗急性髓性白血病(AML)的一种有前景的方案,在新诊断的患者中临床缓解率较高。然而,大约30%的新诊断患者和大多数复发患者在使用ven/aza后没有达到缓解。我们以前报道过,ven/aza的疗效是基于通过抑制氨基酸代谢的机制根除AML干细胞,这是原始AML细胞驱动氧化磷酸化所需的过程。在本文中,我们证明了对ven/aza的抗性通过上调脂肪酸氧化(FAO)发生,这是由于RAS通路突变或作为复发性疾病的补偿适应而发生的。FAO的使用避免了氨基酸代谢的需要,从而使ven/aza无效。FAO的药理学抑制恢复了耐药AML细胞对ven/aza的敏感性。我们提出抑制FAO作为解决ven/aza抗性的治疗策略。
Venetoclax with azacitidine (ven/aza) has emerged as a promising regimen for acute myeloid leukemia (AML), with a high percentage of clinical remissions in newly diagnosed patients. However, approximately 30% of newly diagnosed and the majority of relapsed patients do not achieve remission with ven/aza. We previously reported that ven/aza efficacy is based on eradication of AML stem cells through a mechanism involving inhibition of amino acid metabolism, a process which is required in primitive AML cells to drive oxidative phosphorylation. Herein we demonstrate that resistance to ven/aza occurs via up-regulation of fatty acid oxidation (FAO), which occurs due to RAS pathway mutations, or as a compensatory adaptation in relapsed disease. Utilization of FAO obviates the need for amino acid metabolism, thereby rendering ven/aza ineffective. Pharmacological inhibition of FAO restores sensitivity to ven/aza in drug resistant AML cells. We propose inhibition of FAO as a therapeutic strategy to address ven/aza resistance.
DOI: 10.1016/j.ccell.2018.10.005
发表时间: 2018-11-12
期刊: Cancer cell
影响因子: 50.3
作者:
Jones CL;Stevens BM;D'Alessandro A;Reisz JA;Culp-Hill R;Nemkov T;Pei S;Khan N;Adane B;Ye H;Krug A;Reinhold D;Smith C;DeGregori J;Pollyea DA;Jordan CT
通讯作者: Jordan CT
DOI: 10.1016/j.stem.2012.12.013
发表时间: 2013-03-07
期刊: CELL STEM CELL
影响因子: 23.9
作者:
Lagadinou, Eleni D.;Sach, Alexander;Callahan, Kevin;Rossi, Randall M.;Neering, Sarah J.;Minhajuddin, Mohammad;Ashton, John M.;Pei, Shanshan;Grose, Valerie;O'Dwyer, Kristen M.;Liesveld, Jane L.;Brookes, Paul S.;Becker, Michael W.;Jordan, Craig T.
通讯作者: Jordan, Craig T.
DOI: 10.1182/blood-2016-02-695312
发表时间: 2016-09-29
期刊: BLOOD
影响因子: 20.3
作者:
Ho, Tzu-Chieh;LaMere, Mark;Becker, Michael W.
通讯作者: Becker, Michael W.
DOI: 10.1007/978-1-4939-9236-2_2
发表时间: 2019-01-01
期刊: HIGH-THROUGHPUT METABOLOMICS: METHODS AND PROTOCOLS
影响因子: --
作者:
Nemkov, Travis;Reisz, Julie A.;D'Alessandro, Angelo
通讯作者: D'Alessandro, Angelo
DOI: 10.3324/haematol.2018.214882
发表时间: 2020-03-01
期刊: HAEMATOLOGICA
影响因子: 10.1
作者:
Kuusanmaki, Heikki;Leppa, Aino-Maija;Heckman, Caroline A.
通讯作者: Heckman, Caroline A.